{"id":22342,"date":"2023-02-01T22:33:00","date_gmt":"2023-02-01T14:33:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22342"},"modified":"2025-01-20T22:38:00","modified_gmt":"2025-01-20T14:38:00","slug":"daewoong-pharmaceutical-licenses-bersiporocin-to-csp-for-greater-china-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22342","title":{"rendered":"Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development"},"content":{"rendered":"\n

South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals (CSP) for its first-in-class PRS inhibitor, bersiporocin. Under the agreement, CSP will hold exclusive development and commercial rights to the drug in Greater China, including mainland China, Hong Kong, Taiwan, and Macau. The deal covers indications for Idiopathic Pulmonary Fibrosis (IPF) and other respiratory diseases.<\/p>\n\n\n\n

Deal Details and Financial Commitments<\/strong>
CSP has committed to a total deal value of USD 336 million, including up to USD 76 million in upfront and development milestone payments to Daewoong. Additionally, Daewoong will receive double-digit royalties on net sales. This partnership underscores CSP’s focus on rare disease and ophthalmology products in China, while leveraging Daewoong’s innovative pipeline.<\/p>\n\n\n\n

IPF: Unmet Medical Needs and Current Treatments<\/strong>
Idiopathic Pulmonary Fibrosis (IPF) is a rare, progressive lung disease characterized by the thickening and hardening of lung tissues, leading to a decline in lung function. With a five-year survival rate of less than 50% at diagnosis, IPF remains a life-threatening condition. Current treatments, including Ofev from Boehringer Ingelheim and Esbriet from Roche, offer limited therapeutic benefits, highlighting significant unmet medical needs.<\/p>\n\n\n\n

Bersiporocin Development and Regulatory Milestones<\/strong>
Bersiporocin has been granted Orphan Drug Designation and Fast Track Designation by the US FDA for the treatment of IPF. In 2022, Daewoong initiated a multi-regional Phase II clinical trial for bersiporocin, supported by the Korea Drug Development Fund. The study is expected to conclude in the first half of 2024. CSP’s involvement in the Greater China region will further advance the drug’s development and commercial potential in addressing IPF and other respiratory diseases.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3238,2648,20,25,24],"class_list":["post-22342","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cs-pharmaceuticals","tag-daewoong-pharmaceutical","tag-finance","tag-potential-first-in-class","tag-rare-orphan-disease-drugs"],"yoast_head":"\nDaewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals (CSP) for its first-in-class PRS inhibitor, bersiporocin. Under the agreement, CSP will hold exclusive development and commercial rights to the drug in Greater China, including mainland China, Hong Kong, Taiwan, and Macau. The deal covers indications for Idiopathic Pulmonary Fibrosis (IPF) and other respiratory diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22342\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22342\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T14:33:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-20T14:38:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22342#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22342\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development\",\"datePublished\":\"2023-02-01T14:33:00+00:00\",\"dateModified\":\"2025-01-20T14:38:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22342\"},\"wordCount\":279,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CS Pharmaceuticals\",\"Daewoong Pharmaceutical\",\"Finance\",\"Potential first-in-class\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22342#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22342\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22342\",\"name\":\"Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-01T14:33:00+00:00\",\"dateModified\":\"2025-01-20T14:38:00+00:00\",\"description\":\"South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals (CSP) for its first-in-class PRS inhibitor, bersiporocin. Under the agreement, CSP will hold exclusive development and commercial rights to the drug in Greater China, including mainland China, Hong Kong, Taiwan, and Macau. The deal covers indications for Idiopathic Pulmonary Fibrosis (IPF) and other respiratory diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22342#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22342\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22342#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development - Insight, China's Pharmaceutical Industry","description":"South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals (CSP) for its first-in-class PRS inhibitor, bersiporocin. Under the agreement, CSP will hold exclusive development and commercial rights to the drug in Greater China, including mainland China, Hong Kong, Taiwan, and Macau. The deal covers indications for Idiopathic Pulmonary Fibrosis (IPF) and other respiratory diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22342","og_locale":"en_US","og_type":"article","og_title":"Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22342","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-01T14:33:00+00:00","article_modified_time":"2025-01-20T14:38:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22342#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22342"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development","datePublished":"2023-02-01T14:33:00+00:00","dateModified":"2025-01-20T14:38:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22342"},"wordCount":279,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CS Pharmaceuticals","Daewoong Pharmaceutical","Finance","Potential first-in-class","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22342#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22342","url":"https:\/\/flcube.com\/?p=22342","name":"Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-01T14:33:00+00:00","dateModified":"2025-01-20T14:38:00+00:00","description":"South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals (CSP) for its first-in-class PRS inhibitor, bersiporocin. Under the agreement, CSP will hold exclusive development and commercial rights to the drug in Greater China, including mainland China, Hong Kong, Taiwan, and Macau. The deal covers indications for Idiopathic Pulmonary Fibrosis (IPF) and other respiratory diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22342#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22342"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22342#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22342"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22342\/revisions"}],"predecessor-version":[{"id":22344,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22342\/revisions\/22344"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}